Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

PHASE2CompletedINTERVENTIONAL
Enrollment

438

Participants

Timeline

Start Date

February 19, 2018

Primary Completion Date

January 24, 2019

Study Completion Date

January 30, 2019

Conditions
Overactive Bladder
Interventions
DRUG

Solabegron immediate release tablets, low dose

twice daily for 12 weeks.

DRUG

Solabegron immediate release tablets, high dose

twice daily for 12 weeks.

DRUG

Matching Placebo

twice daily for 12 weeks.

Trial Locations (86)

10016

Velicept Investigative Site - New York, New York

14221

Velicept Investigative Site - Williamsville, Williamsville

23507

Velicept Investigative Site - Norfolk, Norfolk

23606

Velicept Investigative Site - Newport News, Newport News

27103

Velicept Investigative Site - Winston-Salem, Winston-Salem

28203

Velicept Investigative Site - Charlotte, Charlotte

28401

Velicept Investigative Site - Wilmington, Wilmington

29464

Velicept Investigative Site - Mt. Pleasant, Mt. Pleasant

29572

Velicept Investigative Site - Myrtle Beach, Myrtle Beach

30060

Velicept Investigative Site - Marietta, Marietta

32055

Velicept Investigative Site - Lake City, Lake City

32081

Velicept Investigative Site - Ponte Vedra, Ponte Vedra

32720

Velicept Investigative Site - Deland, DeLand

33135

Velicept Investigative Site - Miami, Miami

33166

Velicept Investigative Site - Doral, Doral

33176

Velicept Investigative Site - Miami, Miami

33186

Velicept Investigative Site - Miami, Miami

33409

Velicept Investigative Site - West Palm Beach, West Palm Beach

33458

Velicept Investigative Site - Jupiter, Jupiter

33761

Velicept Investigative Site - Clearwater, Clearwater

33880

Velicept Investigative Site - Winter Haven, Winter Haven

34952

Velicept Investigative Site - Port St Lucie, Port Saint Lucie

35205

Velicept Investigative Site - Birmingham, Birmingham

36542

Velicept Investigative Site - Gulf Shores, Gulf Shores

36608

Velicept Investigative Site - Mobile, Mobile

37203

Velicept Investigative Site - Nashville, Nashville

37920

Velicept Investigative Site - Knoxville, Knoxville

38305

Velicept Investigative Site - Jackson, Jackson

40291

Velicept Investigative Site - Louisville, Louisville

43123

Velicept Investigative Site - Columbus, Columbus

43302

Velicept Investigative Site - Marion, Marion

44122

Velicept Investigative Site - Cleveland, Cleveland

44130

Velicept Investigative Site - Middleburg Heights, Middleburg Heights

45236

Velicept Investigative Site - Cincinnati, Cincinnati

46036

Velicept Investigative Site - Elwood, Elwood

47714

Velicept Investigative Site - Evansville, Evansville

49009

Velicept Investigative Site - Kalamazoo, Kalamazoo

53142

Velicept Investigative Site - Kenosha, Kenosha

60084

Velicept Investigative Site - Wauconda, Wauconda

63141

Velicept Investigative Site - St. Louis, St Louis

67114

Velicept Investigative Site - Newton, Newton

68114

Velicept Investigative Site - Omaha, Omaha

70001

Velicept Investigative Site - Metairie, Metairie

70115

Velicept Investigative Site - New Orleans, New Orleans

71106

Velicept Investigative Site - Shreveport, Shreveport

72212

Velicept Investigative Site - Little Rock, Little Rock

76550

Velicept Investigative Site - Lampasas, Lampasas

77702

Velicept Investigative Site - Beaumont, Beaumont

78209

Velicept Investigative Site - San Antonio, San Antonio

78229

Velicept Investigative Site - San Antonio, San Antonio

78249

Velicept Investigative Site - San Antonio, San Antonio

78735

Velicept Investigative Site - Austin, Austin

80209

Velicept Investigative Site - Denver, Denver

Velicept Investigative Site - Longview, Longview

83221

Velicept Investigative Site - Blackfoot, Blackfoot

83642

Velicept Investigative Site - Meridian, Meridian

84015

Velicept Investigative Site - Clinton, Clinton

84088

Velicept Investigative Site - West Jordan, West Jordan

84107

Velicept Investigative Site - Salt Lake City, Salt Lake City

84124

Velicept Investigative Site - Salt Lake City, Salt Lake City

84790

Velicept Investigative Site - St. George, St. George

85283

Velicept Investigative Site - Tempe, Tempe

87102

Velicept Investigative Site - Albuquerque, Albuquerque

87504

Velicept Investigative Site - Tucson, Tucson

89119

Velicept Investigative Site - Las Vegas, Las Vegas

90017

Velicept Investigative Site - Los Angeles, Los Angeles

90720

Velicept Investigative Site - Los Alamitos, Los Alamitos

91007

Velicept Investigative Site - Arcadia, Arcadia

91303

Velicept Investigative Site - Canoga Park, Canoga Park

91360

Velicept Investigative Site - Thousand Oaks, Thousand Oaks

92078

Velicept Investigative Site - San Marcos, San Marcos

92103

Velicept Investigative Site - San Diego, San Diego

92123

Velicept Investigative Site - San Diego, San Diego

92647

Velicept Investigative Site - Huntington Beach, Huntington Beach

92801

Velicept Investigative Site - Anaheim, Anaheim

92860

Velicept Investigative Site - Norco, Norco

95821

Velicept Investigative Site - Sacramento, Sacramento

98405

Velicept Investigative Site - Tacoma, Tacoma

06708

Velicept Investigative Site - Waterbury, Waterbury

02131

Velicept Investigative Site - Boston, Boston

02740

Velicept Investigative Site - New Bedford, New Bedford

02760

Velicept Investigative Site - North Attleborro, North Attleboro

02472

Velicept Investigative Site - Watertown, Watertown

08724

Velicept Investigative Site - Brick, Brick

08043

Velicept Investigative Site - Vorhees, Voorhees Township

02818

Velicept Investigative Site - Warwick, Warwick

All Listed Sponsors
lead

Velicept Therapeutics, Inc.

INDUSTRY

NCT03475706 - Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women | Biotech Hunter | Biotech Hunter